Moderna shares surge after U.S.
Photo: Leon Neal/AP

Moderna shares surge after U.S. FDA to consider its flu shot

Pharmaceutical company Moderna surged 8 percent in U.S. premarket trading after the announcement that the U.S. FDA will consider its flu shot.

Advertisement

The Swedish Medicines Agency has previously rejected Moderna's application to test the vaccine. The vaccine is an mRNA vaccine, and Moderna is seeking full approval to offer the vaccine to adults aged 50 to 64.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All